Celldex Therapeutics(CLDX)
HAMPTON, NJBiotechnology
Focus: Celldex is a publicly traded biotechnology company focused on small molecules, biologics, and vaccines across infectious diseases and oncology. With ~750 employees and $7M revenue in FY2025, it operates as a clinical-stage biotech with an expansive pipeline.
Profile data last refreshed 28m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
20+20 this month
Hot — 21 jobs added in 30d
Net +20 (21 new, 1 removed). Aggressive expansion phase.
Should You Work at Celldex Therapeutics?
AI assessmentBest suited for early-stage clinical development scientists and immunologists willing to tolerate high execution risk for equity upside and scientific breadth; avoid if seeking stability or near-term revenue participation.
Why Work Here
- Diverse pipeline of 30+ programs spanning oncology, immunology, and infectious disease provides exposure to multiple therapeutic modalities and indications.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$7M
Pipeline & Clinical Trials
glembatumumab vedotin
Metastatic gpNMB Expressing Triple Negative Breast CancerClinical Trials (1)
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
N/AHelp build intelligence for Celldex Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.